Abstract
Angiogenesis inhibitors have a major role in the treatment of varying cancers today. While originally thought to be independent of resistance, increasing data suggests varying mechanisms that bring about drug resistance, either intrinsically or through adaptation. The role of vascular endothelial growth factor single nucleotide polymorphisms (VEGF SNPs) in terms of therapeutic response and toxicity has increasingly been recognized, as well as its potential for contributing to drug resistance. This review will focus on theories, preclinical models, and clinical trials that help elucidate the mechanisms of resistance and clinical response to angiogenesis inhibitors.
Keywords: Angiogenesis, angiogenesis inhibitors, polymorphisms, drug resistance, toxicity
Anti-Cancer Agents in Medicinal Chemistry
Title: Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors
Volume: 10 Issue: 8
Author(s): Jahan Tavakoli and Jeanny B. Aragon-Ching
Affiliation:
Keywords: Angiogenesis, angiogenesis inhibitors, polymorphisms, drug resistance, toxicity
Abstract: Angiogenesis inhibitors have a major role in the treatment of varying cancers today. While originally thought to be independent of resistance, increasing data suggests varying mechanisms that bring about drug resistance, either intrinsically or through adaptation. The role of vascular endothelial growth factor single nucleotide polymorphisms (VEGF SNPs) in terms of therapeutic response and toxicity has increasingly been recognized, as well as its potential for contributing to drug resistance. This review will focus on theories, preclinical models, and clinical trials that help elucidate the mechanisms of resistance and clinical response to angiogenesis inhibitors.
Export Options
About this article
Cite this article as:
Tavakoli Jahan and B. Aragon-Ching Jeanny, Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (8) . https://dx.doi.org/10.2174/187152010794473948
DOI https://dx.doi.org/10.2174/187152010794473948 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Comparison Between the Maximum Standard Uptake Value and the Ratio of Lymph Node to Primary Tumor Attenuation in Head and Neck Cancers: A Prospective Study
Current Medical Imaging Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: The Triumph of Radiobiology
Reviews on Recent Clinical Trials MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology The Anti-Tumor Mechanism and Target of Triptolide Based on Network Pharmacology and Molecular Docking
Recent Patents on Anti-Cancer Drug Discovery Downregulation of CCKBR Expression Inhibits the Proliferation of Gastric Cancer Cells, Revealing a Potential Target for Immunotoxin Therapy
Current Cancer Drug Targets Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry Recent US Patents on Extracellular Matrix in Tissue Engineering and Regenerative Medicine
Recent Patents on Regenerative Medicine Crotamine, a Small Basic Polypeptide Myotoxin from Rattlesnake Venom with Cell-Penetrating Properties
Current Pharmaceutical Design Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets [General Articles] Intracellular Thiol Concentration Modulating Inflammatory Response: Influence on the Regulation of Cell Functions Through Cysteine Prodrug Approach
Current Medicinal Chemistry Targeting Prostate Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Azelaic Acid: A Promising Agent for Dermatological Applications
Current Drug Therapy The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry Targeting Cytokines for Morphine Tolerance: A Narrative Review
Current Neuropharmacology Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry Berberine Exhibits Antitumor Effects in Human Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design